Expertise in
10
conditions

Gwenaelle Gravis

Marseille, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
10
conditions
Marseille, FR 

Overview

Gwenaelle Gravis practices in Marseille, France. Ms. Gravis is highly rated in 10 conditions, according to our data. Her top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Bladder Cancer, Orchiectomy, and Nephrectomy.

Her clinical research consists of co-authoring 246 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender

Female

Locations

Marseille, France
Other Locations
Aix-en-provence, France
232, Boulevard De Sainte Marguerite 13009 Marseille, Saint-etienne, 13009, France
INSERM UMR 1068, St. Quentin En Yvelines All In France, Saint-quentin-sur-indrois, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
A Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases
Enrollment Status: Recruiting
Publish Date: January 13, 2026
Intervention Type: Radiation
Study Drug: Pursuit of ongoing systemic treatment
Study Phase: Phase 2
Dose Intensification Phase II Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis. TICE Protocol : Paclitaxel and Ifosfamide Followed by Carboplatine and Etoposide Intensification With Individual Carboplatine Dose Adjustment.
Dose Intensification Phase II Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis. TICE Protocol : Paclitaxel and Ifosfamide Followed by Carboplatine and Etoposide Intensification With Individual Carboplatine Dose Adjustment.
Enrollment Status: Completed
Publish Date: April 14, 2026
Intervention Type: Drug, Procedure
Study Phase: Phase 2
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)
A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)
Enrollment Status: Completed
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
A Prospective Randomised Phase III Study Of Androgen Deprivation Therapy With Or Without Docetaxel With Or Without Local Radiotherapy With Or Without Abiraterone Acetate And Prednisone In Patients With Metastatic Hormone-Naïve Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2024
Intervention Type: Other, Radiation, Drug
Study Drugs: Abiraterone acetate, Docetaxel
Study Phase: Phase 3
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
CYCLONE 1: A Phase 2 Study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With a Novel Hormonal Agent and Taxane-based Chemotherapy
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Drug
Study Drug: Abemaciclib
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (Panel FoundationOne) Versus a Limited Molecular Profiling Panel (Panel CONTROL) in Advanced Solid Tumors.
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Genetic
Study Phase: Not Applicable
Prospective Multicentric Evaluation of a Bladder Preservation Strategy Using a Combination of Neoadjuvant Chemotherapy and Optimal Bladder Transurethral Resection in Patients With a Urothelial Carcinoma
Prospective Multicentric Evaluation of a Bladder Preservation Strategy Using a Combination of Neoadjuvant Chemotherapy and Optimal Bladder Transurethral Resection in Patients With a Urothelial Carcinoma
Enrollment Status: Terminated
Publish Date: December 30, 2021
Intervention Type: Drug
Study Drug: Optimal TURB
Study Phase: Phase 2
View 9 Less Clinical Trials

246 Total Publications

Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 07, 2026

Frequently Asked Questions about Gwenaelle Gravis

Is Gwenaelle Gravis a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Gwenaelle Gravis is classified as an Elite expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Gwenaelle Gravis participate in research or clinical trials?

Yes. Gwenaelle Gravis has published 246 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Gwenaelle Gravis's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Gravis's expertise for a condition
ConditionClose
View All 16 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile